Gilead’s Remdesivir Pricing Sets ‘Promising’ Precedent For Future COVID-19 Drugs
Executive Summary
Highly anticipated decision bodes well for pricing of other future treatments for the disease, the US Institute for Clinical and Economic Review suggests.